Skip to contentT
Tenax Therapeutics, Inc.
T
TENXTenax Therapeutics, Inc. Released Aug 14, 2023, after the close
10-Q filed Aug 14, 2023, 45 days after period end · 0001654954-23-010758
Q2 2023 · 10-Q
Revenue—
Net Income-$1.11M-$1.11MN/M vs Q2 2022N/M vs Q1 2023 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Tenax Therapeutics, Inc. · CIK 34956 · Engraved from SEC EDGAR
Operating Income$1,236,160−56.8% Operating Cash Flowderived-$922,966N/M Free Cash Flowderived-$924,568N/M ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end